The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, University of Illinois Chicago, Massachusetts General Hospital, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, St. Luke's-Roosevelt Hospital Center, Duke Medical Center, University of Washington, Rutgers Cancer Institute, University of Medicine and Dentistry of New Jersey
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2265463209